Avelumab - Biologic Drug Details

Summary for avelumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for avelumab

Recent Clinical Trials for avelumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Liza Villaruz, MD	PHASE2
Institut fr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	PHASE2
University Hospital Tbingen	PHASE2

See all avelumab clinical trials

Pharmacology for avelumab

Mechanism of Action	Programmed Death Ligand-1 Antagonists Programmed Death Ligand-1-directed Antibody Interactions
Established Pharmacologic Class	Programmed Death Ligand-1 Blocker
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for avelumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for avelumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,023,656	2037-04-28	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,233,251	2036-02-22	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,487,147	2037-03-09	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,501,544	2036-11-29	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,550,175	2038-11-16	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,703,812	2036-12-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for avelumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,001,483	2036-06-24	Patent claims search
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,143,723	2038-06-01	Patent claims search
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,172,808	2038-06-01	Patent claims search
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,195,175	2037-04-06	Patent claims search
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,195,188	2037-09-01	Patent claims search
Emd Serono, Inc.	BAVENCIO	avelumab	Injection	761049	10,206,910	2035-11-06	Patent claims search

International Patents for avelumab

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017174824
South Korea	20180085801
Canada	2856895
Japan	2022036208
Japan	2015500207
Canada	2947660

Supplementary Protection Certificates for avelumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
122020000082	Germany		PRODUCT NAME: AVELUMAB; REGISTRATION NO/DATE: EU1/17/1214 20170918
PA2021001,C2785375	Lithuania		PRODUCT NAME: AVELUMABAS; REGISTRATION NO/DATE: EU/1/17/1214 20170918
20C1068	France		PRODUCT NAME: AVELUMAB; REGISTRATION NO/DATE: EU/1/17/1214 20170920
SPC/GB21/009	United Kingdom		PRODUCT NAME: AVELUMAB; REGISTERED: UK EU 1/17/1214 (NI) 20170920; UK PLGB 11648/0262 20170920
LUC00194	Luxembourg		PRODUCT NAME: AVELUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1214 20170920
2021003	Norway		PRODUCT NAME: AVELUMAB; REG. NO/DATE: EU/1/17/1214/001 20170918

Avelumab Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is Avelumab's Therapeutic Indication and Mechanism of Action?

Avelumab is a human anti-PD-L1 IgG1 antibody. Its mechanism of action involves blocking the interaction between programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) receptors. This blockade prevents tumor cells from evading the immune system by deactivating T cells. PD-L1 is often expressed on tumor cells and in the tumor microenvironment, and its interaction with PD-1 on T cells leads to immune suppression. By inhibiting this interaction, avelumab restores the ability of T cells to recognize and attack cancer cells.

What are the Approved Indications for Avelumab?

Avelumab has received regulatory approval for several indications across different cancer types. Key approved uses include:

• Urothelial Carcinoma: Approved for patients with locally advanced or metastatic urothelial carcinoma who have progressed with platinum-containing chemotherapy, including after prior treatment with a PD-1/PD-L1 inhibitor. This indication was based on data from the JAVELIN Bladder 100 trial.
• Merkel Cell Carcinoma: Approved for adult and pediatric patients with metastatic Merkel cell carcinoma (MCC). This was one of the earliest approvals for avelumab and was based on its durable response rates in this aggressive skin cancer.
• Non-Small Cell Lung Cancer (NSCLC): Approved in combination with axitinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors express PD-L1.

Future indications are being explored in ongoing clinical trials.

What is the Competitive Landscape for Avelumab?

The immuno-oncology market, particularly the PD-1/PD-L1 inhibitor space, is highly competitive. Avelumab competes with several established and emerging agents. Key competitors include:

• Pembrolizumab (Keytruda, Merck & Co.): A leading PD-1 inhibitor with broad approvals across numerous cancer types.
• Nivolumab (Opdivo, Bristol Myers Squibb): Another prominent PD-1 inhibitor with extensive clinical utility.
• Atezolizumab (Tecentriq, Genentech/Roche): A PD-L1 inhibitor with significant market share.
• Durvalumab (Imfinzi, AstraZeneca): A PD-L1 inhibitor approved for specific indications, notably in lung cancer.

Competition is characterized by rapid clinical development, expanding approved indications, and combinations with other therapies to improve efficacy. The efficacy and safety profile of each agent, as well as their positioning in treatment algorithms (e.g., first-line vs. second-line, monotherapy vs. combination), are critical differentiators.

What is the Market Size and Growth Trajectory of Avelumab?

The market for immuno-oncology drugs, including PD-1/PD-L1 inhibitors, has experienced substantial growth. While specific market size figures for avelumab are proprietary to its developers, the broader immuno-oncology market is projected to continue its upward trajectory. Global oncology drug market reports estimate the immuno-oncology segment to reach tens of billions of dollars annually within the next five years.

Avelumab's market penetration is influenced by:

• Approved Indications: The breadth and depth of its approved uses.
• Clinical Trial Outcomes: Success in demonstrating superior efficacy or novel benefits in ongoing studies.
• Reimbursement and Payer Policies: Access and coverage decisions by healthcare payers.
• Competitive Pricing and Discounting: Market dynamics that influence net sales.
• Geographic Market Penetration: Expansion into new international markets.

The growth trajectory is expected to be driven by its established indications and potential expansion into new therapeutic areas or combinations.

What are the Key Clinical Trials and Their Impact on Avelumab's Market Position?

Several pivotal clinical trials have shaped avelumab's market position. The most significant include:

• JAVELIN Bladder 100: This Phase III trial demonstrated a statistically significant improvement in overall survival (OS) for patients with previously untreated, locally advanced or metastatic urothelial carcinoma who received avelumab plus best supportive care compared to best supportive care alone. This trial was crucial for its approval in this indication and positioned avelumab as a first-line maintenance option.
• JAVELIN Merkel 200: This Phase II trial provided the basis for avelumab's approval in metastatic Merkel cell carcinoma, showing high response rates and durable responses in a patient population with limited treatment options.
• JAVELIN Lung 100/101 and other NSCLC trials: Studies in NSCLC have evaluated avelumab both as monotherapy and in combination with chemotherapy or targeted agents, leading to its approval in combination with axitinib for first-line metastatic NSCLC.

Ongoing trials are investigating avelumab in various other solid tumors, often in combination regimens, to further expand its therapeutic reach and potentially improve outcomes.

What are the Financial Performance and Revenue Projections for Avelumab?

Detailed financial performance data for individual drugs like avelumab is typically reported by their respective pharmaceutical companies, often as part of a broader portfolio. Avelumab is co-developed and co-marketed by Pfizer and Merck KGaA, Darmstadt, Germany.

As of the latest available reports, sales data for avelumab have shown consistent growth, particularly following the approval of its first-line urothelial carcinoma indication. While exact figures vary by reporting period, sales have reached into the hundreds of millions of dollars annually. For example, in recent fiscal years, avelumab has contributed significant revenue to its parent companies' oncology portfolios.

Revenue projections are influenced by:

• Market Penetration in Approved Indications: The extent to which it is prescribed for its current uses.
• New Indication Approvals: Successful outcomes in ongoing clinical trials could unlock new revenue streams.
• Competitive Dynamics: Pricing pressures and market share erosion due to competing therapies.
• Patent Expirations and Biosimilar Entry: Future impact on market exclusivity and pricing.
• Global Market Expansion: Penetration into emerging markets.

Industry analysts project continued growth for avelumab, driven by its established role in urothelial carcinoma and potential expansion into other oncology indications. However, the competitive intensity of the immuno-oncology market necessitates continuous innovation and strategic market positioning.

What are the Key Regulatory and Patent Considerations for Avelumab?

Avelumab's market exclusivity is protected by a combination of regulatory approvals and patent protection.

Regulatory Status:

• US FDA Approvals: Avelumab has received accelerated and full approvals from the U.S. Food and Drug Administration (FDA) for its key indications. These approvals are subject to post-marketing surveillance and may require further clinical studies to confirm benefit.
• EMA Approvals: The European Medicines Agency (EMA) has also granted marketing authorizations for avelumab in its approved indications.
• Other Jurisdictions: Approvals have been secured in numerous other global markets.

Patent Landscape:

The patent landscape for biologics like avelumab is complex and extends to composition of matter, manufacturing processes, and methods of use. Key patent considerations include:

• Core Antibody Patents: Patents covering the avelumab antibody itself, its sequence, and binding characteristics.
• Manufacturing Patents: Patents related to the processes used to produce the biologic drug at scale.
• Method of Use Patents: Patents covering the use of avelumab in specific indications or in combination with other therapies.
• Patent Term Extensions: In many jurisdictions, patent terms can be extended to compensate for regulatory review delays.
• Exclusivity Periods: Regulatory bodies may grant additional periods of market exclusivity independent of patent protection.

The expiration of key patents and the potential for biosimilar competition are critical factors for long-term revenue sustainability. Companies actively seek to strengthen their patent portfolios and utilize regulatory exclusivity to maintain market share.

What are the Future Growth Opportunities and Challenges for Avelumab?

Growth Opportunities:

• Expansion into New Indications: Ongoing clinical trials in a variety of solid tumors (e.g., gastric, ovarian, endometrial cancers) represent significant potential for new approvals.
• Combination Therapies: The development and approval of novel combination regimens with chemotherapy, targeted agents, or other immunotherapies could enhance efficacy and broaden patient populations.
• First-Line Treatment Settings: Establishing avelumab as a preferred first-line option in additional cancer types beyond its current indications.
• Geographic Expansion: Penetrating under-served or emerging markets.
• Biomarker-Driven Therapies: Refining patient selection strategies based on specific biomarkers to improve treatment outcomes.

Challenges:

• Intense Competition: The PD-1/PD-L1 inhibitor market is crowded, with multiple established players and ongoing development of new agents.
• Evolving Treatment Paradigms: The rapid pace of scientific advancement in oncology means treatment guidelines can shift quickly.
• Pricing and Reimbursement Pressures: Healthcare systems face increasing cost containment measures, impacting drug pricing and market access.
• Clinical Trial Success Rates: The inherent risks and high failure rates associated with oncology drug development.
• Patent Expirations and Biosimilar Entry: The eventual loss of market exclusivity will lead to price erosion and increased competition from biosimil products.
• Immunogenicity and Side Effects: As with all biologics, potential for immune reactions and management of side effects are ongoing considerations.

Key Takeaways

Avelumab is an established PD-L1 inhibitor with key indications in urothelial carcinoma, Merkel cell carcinoma, and NSCLC. Its market position is shaped by competitive pressures in the immuno-oncology space and the critical outcomes of pivotal trials like JAVELIN Bladder 100, which solidified its role as a first-line maintenance therapy in urothelial carcinoma. While detailed financial figures are proprietary, avelumab has contributed significant revenue, with continued growth projected based on its existing approvals and the potential for expansion into new indications and combination therapies. Key challenges include intense competition, evolving treatment paradigms, and the eventual threat of biosimilar entry. Regulatory and patent landscapes are crucial for maintaining market exclusivity.

Frequently Asked Questions

1. What is the primary differentiator for avelumab compared to other PD-1/PD-L1 inhibitors? Avelumab's differentiated profile includes its specific indication for first-line maintenance therapy in urothelial carcinoma following chemotherapy, supported by overall survival benefits demonstrated in the JAVELIN Bladder 100 trial.

2. What is the current status of avelumab's patent protection and when is biosimilar competition expected? The patent landscape for avelumab is multifaceted, covering the antibody itself, manufacturing, and methods of use. Specific patent expiration dates and the exact timing of potential biosimilar entries are subject to ongoing legal and regulatory developments but are anticipated to occur in the coming years, impacting market exclusivity.

3. Beyond its current approved indications, what are the most promising areas for avelumab's future development? Promising areas for avelumab's future development include its investigation in combination regimens with other immunotherapies, chemotherapy, and targeted agents across a range of solid tumors, with a focus on early-line treatment settings.

4. How do payer policies and reimbursement decisions impact avelumab's market access and revenue? Payer policies and reimbursement decisions significantly influence avelumab's market access by determining patient eligibility, cost-sharing, and formulary placement. Favorable reimbursement is critical for uptake and achieving revenue potential.

5. What is the projected annual revenue for avelumab in the next three to five years? Specific future revenue projections for avelumab are proprietary and subject to dynamic market factors. However, industry analysts generally forecast continued revenue growth, driven by expanding indications and its established position, though the precise figures are sensitive to competitive dynamics and clinical outcomes.

Citations

[1] Merck KGaA, Darmstadt, Germany. (n.d.). Avelumab (BAVENCIO®). Retrieved from https://www.emdgroup.com/en/products/avelumab.html

[2] Pfizer Inc. (n.d.). BAVENCIO® (avelumab). Retrieved from https://www.pfizer.com/science/drug-development/avelumab

[3] Powles, T., O’Donnell, P. H., Massard, C., Loriot, Y., Pintilie, M., Vulsteke, C., ... & Bellmunt, A. (2021). Primary overall survival results of the JAVELIN Bladder 100 trial: a phase III, randomized, multicenter, open-label study of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment in advanced urothelial carcinoma. Journal of Clinical Oncology, 39(15), 1643-1651. DOI: 10.1200/JCO.20.03358

[4] FDA. (n.d.). Drug Approval Packages - BAVENCIO. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209271Orig1s037,209271Orig1s038.pdf (Note: This is a representative link to an FDA approval package; specific approval documents may vary.)

[5] National Cancer Institute. (n.d.). NCI Drug Dictionary. Retrieved from https://www.cancer.gov/publications/dictionaries/cancer-drug/def/avelumab